{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-016110","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.465879+00:00","generated_at":"2026-06-26T04:07:32.485622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viking Q1 2022 net loss $16.1M; VK2809 enrollment continues, VK2735 Phase 1 ongoing","bullets":["Net loss $16.1M ($0.21/share) vs $14.0M ($0.19/share) in Q1 2021; R&D up to $12.6M.","Cash and investments $184.9M at March 31, 2022, down from $202.1M at Dec 31, 2021.","Phase 2b VOYAGE study of VK2809 for NASH expects to complete enrollment in 2H22.","Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; results expected by year-end.","VK0214 for X-ALD on clinical hold, expects to submit requested preclinical data to FDA in 2Q22."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-016110","json":"https://secwatch.observer/filing/0001564590-22-016110.json","markdown":"https://secwatch.observer/filing/0001564590-22-016110.md","text":"https://secwatch.observer/filing/0001564590-22-016110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/0001564590-22-016110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000156459022016110/vktx-8k_20220427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:07:32.485622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}